Abbott‘s BVS is a device designed to restore blood flow by opening a clogged vessel and providing support while it heals and once the vessel can remain open without the extra support, the bioresorbable scaffold is designed to be slowly metabolised and eventually dissolve and disappear from the body.

Abbott presents long-term clinical data evaluating the safety and performance of a fully bioresorbable drug eluting vascular scaffold.

Results from the first stage of the Absorb trial with 30 patients demonstrated that Abbott’s BVS successfully treated coronary artery disease and was resorbed into the walls of the treated arteries.

The BVS device is made of polylactide, a proven biocompatible material that is commonly used in medical implants such as dissolving sutures.

The Absorb Extend trial is a large-scale, single-arm trial that will enroll approximately 1,000 patients from up to 100 centers in Europe, Asia Pacific, Canada and Latin America.

Abbott’s bioresorbable technology delivers everolimus, an anti-proliferative drug, developed by Novartis Pharma AG and is licensed to Abbott by Novartis for use on its drug eluting vascular devices.

Fortis-Escorts Heart Institute Ashok Seth said Abbott’s BVS has the potential to revolutionise how we treat patients with coronary artery disease because there is no permanent metal implant, once the BVS is resorbed by the body, natural vessel function may be restored.